Effects of coenzyme Q 10 in early Parkinson disease: Evidence of slowing of the functional decline

Archives of Neurology

Volumn 59, Issue 10, 2002, Pages 1541-1550

  Shults, Clifford W ^a,b,o,p,q   Oakes, David ^c   Kieburtz, Karl ^c   Flint Beal, M ^d   Haas, Richard ^a   Plumb, Sandy ^c   Juncos, Jorge L ^e   Nutt, John ^f,g   Shoulson, Ira ^c   Carter, Julie ^g   Kompoliti, Katie ^h   Perlmutter, Joel S ⁱ   Reich, Stephen ^j   Stern, Matthew ^k   Watts, Ray L ^e   Kurlan, Roger ^c   Molho, Eric ^l   Harrison, Madaline ^m   Lew, Mark ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e EMORY UNIVERSITY   (United States)

^f BALTIMORE VA MEDICAL CENTER   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h RUSH UNIVERSITY MEDICAL CENTER   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l ALBANY MEDICAL COLLEGE   (United States)

^m UNIVERSITY OF VIRGINIA   (United States)

ⁿ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^o Enzymatic Therapy Inc   (United States)

^p Vitaline Corp   (United States)

^q Glycobiology Core Resources Regents of the University of California USCD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; UBIDECARENONE; ANTIOXIDANT; DRUG DERIVATIVE; UBIQUINONE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FALLING; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PARKINSON DISEASE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING; SINUSITIS; VERTIGO; VIRUS INFECTION; AGED; CELL PROTECTION; DISABLED PERSON; DISEASE COURSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIOXIDANTS; CYTOPROTECTION; DISABLED PERSONS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME; UBIQUINONE;

EID: 0036771852     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.10.1541     Document Type: Article

References (48)

1. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin. 1996; 14:317-335.
2. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol. 2000;247 (suppl 2): II3-II10
3. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 1996;55:259-272.
4. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci. 1999;22:123-144.
5. Vaughan JR, Davis MB, Wood NW. Genetics of parkinsonism: a review. Ann Hum Genet. 2001;65(pt 2):111-126.
6. Sherer TB, Betarbet R, Greenamyre JT. Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs. 2001;2:657-662.
7. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
8. Przedborski S, Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov Disord. 1998; 13(suppl 1):35-38.
9. Schapira AHV, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem. 1990;55:2142-2145.
10. Turner C, Schapira AH. Mitochondrial dysfunction in neurodegenerative disorders and ageing. Adv Exp Med Biol. 2001;487:229-251.
11. Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719-723.
12. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV. Platelet mitochondrial function in Parkinson's disease. Ann Neurol. 1992;32:782-788.
13. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm. 1992;4:27-34.
14. Benecke R, Strümper P, Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain. 1993;116:1451-1463.
15. Haas R, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol. 1995; 37:714-722.
16. Shults CW, Nasirian F, Ward DM, et al. Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Neurology. 1995; 45:344-348.
17. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301-1306.
18. 10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42:261-264.
19. 10 level in Parkinson syndrome. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and Clinical Aspects of Coenzyme Q. New York, NY: Elsevier Science Publishers; 1991:159-166.
20. 10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783:109-114.
21. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892-8897.
22. 10 in parkinsonian patients. Neurology. 1998;50:793-795.
23. Folstein MF, Folstein SE, McHugh P. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
24. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1988; 45:742-747.
25. Lang AE. Clinical rating scales and videotape analysis. In: Koller WC, Paulson G, eds. Therapy of Movement Disorders. 2nd ed. New York, NY: Marcel Dekker Inc; 1995:21-46.
26. Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord. 1994;9:76-83.
27. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD. Teaching tape for the motor section of the Unified Parkinson's Disease Rating Scale. Mov Disord. 1995;10:263-266.
28. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale. Mov Disord. 1994;9:89-91.
29. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981:138-159.
30. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
31. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med. 1991;10:1595-1605.
32. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. JAMA. 1997;278:125-130.
33. Cox DR, Oakes D. Analysis of Survival Data. New York, NY: Chapman & Hall; 1984.
34. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Ann Neurol. 1993;33:350-356.
35. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalopathy. Proc Natl Acad Sci U S A. 1989;86:2379-2382.
36. 10 deficiency in a woman with myopathy, recurrent myoglobinuria and seizures [abstract]. Neurology. 1996; 46(suppl 2):A231.
37. 10 deficiency. Neurology. 2001;56:849-855.
38. 10 deficiency. Neurology. 2001;57:515-518.
39. Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol. 2001;49:590-596.
40. 10 in chronic heart failure, angina, and hypertension. Pharmacotherapy. 2001;7:797-806.
41. 10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636-640.
42. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci. 1990; 100:70-78.
43. Zierz S, von Wersebe O, Bleistein J, Jerusalem F. Exogenous coenzyme Q (CoQ) fails to increase CoQ in skeletal muscle of two patients with mitochondrial myopathies. J Neurol Sci. 1990;95:283-290.
44. 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology. 1993;43:884-890.
45. Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta. 1995;1271:275-280.
46. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42:1142-1146.
47. 10 and remacemide in Huntington's disease. Neurology. 2001;57:397-404.
48. 10. Ann Neurol. 1997;41:160-165.